Stockscreener 앱 받기
0.7382
1.01%
-0.0075
전일 마감가:
$0.7457
열려 있는:
$0.72
하루 거래량:
66,111
Relative Volume:
1.39
시가총액:
$22.60M
수익:
$8.59M
순이익/손실:
$-17.07M
주가수익비율:
-1.2102
EPS:
-0.61
순현금흐름:
$-21.90M
1주 성능:
+1.40%
1개월 성능:
-13.05%
6개월 성능:
-48.38%
1년 성능:
-15.27%
1일 변동 폭
$0.70
$0.7382
1주일 범위
$0.70
$0.76
52주 변동 폭
$0.70
$1.88
Durect Corp Stock (DRRX) Company Profile
명칭
Durect Corp
전화
(408) 777-1417
주소
10240 BUBB ROAD, CUPERTINO, CA
DRRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.7382 | 22.60M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-30 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-12 | 개시 | ROTH Capital | Buy |
| 2020-07-31 | 개시 | Oppenheimer | Outperform |
| 2020-01-31 | 개시 | B. Riley FBR | Buy |
| 2019-11-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | 재확인 | Laidlaw | Buy |
| 2017-10-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2017-02-28 | 재개 | H.C. Wainwright | Buy |
| 2016-04-25 | 개시 | Rodman & Renshaw | Buy |
| 2015-05-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-05-01 | 재확인 | Stifel | Buy |
| 2013-03-25 | 개시 | Stifel | Buy |
| 2012-11-01 | 다운그레이드 | C.K. Cooper | Buy → Hold |
| 2012-08-17 | 개시 | C.K. Cooper | Buy |
| 2009-06-23 | 개시 | Caris & Company | Buy |
| 2009-03-26 | 개시 | Wedbush Morgan | Hold |
모두보기
Durect Corp 주식(DRRX)의 최신 뉴스
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Exclusive Healthcare Conference Alert: DURECT CEO Reveals Latest Developments - Stock Titan
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect Corp (DRRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
0.69%
자본화:
|
볼륨(24시간):